Summary
The AI statements are largely unsupported by the provided FDA label excerpts, which only address antibacterial stewardship and basic administration instructions. Several claims concern pricing, manufacturer/coupon programs, generic availability/bioequivalence, ER vs IR dosing and pharmacologic benefits, and patent information—none of which are supported in the supplied labeling text.
Category Scores
Accurate Statements
To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin extended-release tablets and other antibacterial drugs, clarithromycin extended-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Supported by Section 1 excerpt: use only for infections proven or strongly suspected to be caused by susceptible bacteria.
Unsupported Statements
The price of Clarithromycin ER (extended-release) can vary depending on dosage, quantity, and the pharmacy where it is purchased.
No pricing information is present in the supplied label excerpts.
The retail price of Clarithromycin ER depends on the specific strength (e.g., 500 mg, 750 mg).
No pricing/strength-to-price relationship is present in the supplied label excerpts.
The retail price of Clarithromycin ER depends on the number of tablets in the prescription bottle.
No pricing/quantity information is present in the supplied label excerpts.
Insurance coverage affects the retail price of Clarithromycin ER, with copays differing based on a patient's health plan.
No payer/cost/coplay information is present in the supplied label excerpts.
Pharmacy pricing strategies can lead to price variations between different retail locations and online pharmacies.
No pharmacy pricing strategy information is present in the supplied label excerpts.
Prescription discount cards and online coupon websites often offer reduced prices for Clarithromycin ER.
No discount card/coupon program information is present in the supplied label excerpts.
Some manufacturers provide savings programs or coupons directly for Clarithromycin ER.
No manufacturer savings/coupon program information is present in the supplied label excerpts.
Local pharmacies may offer ongoing promotions or loyalty programs that can yield discounts for Clarithromycin ER.
No pharmacy promotion/loyalty program information is present in the supplied label excerpts.
For patients with commercial insurance, manufacturer-sponsored copay assistance programs may be available for Clarithromycin ER.
No copay assistance program information is present in the supplied label excerpts.
Extended-release (ER) formulations of medications, including Clarithromycin ER, are generally priced higher than their immediate-release counterparts.
No pricing comparison between ER and immediate-release formulations is present in the supplied label excerpts.
The price difference between ER and immediate-release formulations is attributed to a more complex manufacturing process required for extended-release delivery systems.
No manufacturing/process or pricing attribution is present in the supplied label excerpts.
Extended-release delivery systems are designed to release the medication gradually over a longer period.
No pharmacologic/technological description of ER release is present in the supplied label excerpts.
The ER formulation aims to provide more stable drug levels in the body.
No pharmacokinetic/stability claim is present in the supplied label excerpts.
The ER formulation potentially allows for less frequent dosing.
No dosing-frequency claim is present in the supplied label excerpts.
The ER formulation potentially improves patient adherence.
No adherence claim is present in the supplied label excerpts.
Generic versions of Clarithromycin ER are available.
No information on availability of generics is present in the supplied label excerpts.
The introduction of generic alternatives typically leads to a significant reduction in price compared to the brand-name drug.
No pricing effect of generics is present in the supplied label excerpts.
Generics of Clarithromycin ER are bioequivalent to the brand-name product.
No bioequivalence statement is present in the supplied label excerpts.
Bioequivalent generics contain the same active ingredient and work in the same way as the brand-name product.
No bioequivalence or mechanism/effect sameness statement is present in the supplied label excerpts.
Generic Clarithromycin ER can provide substantial cost savings compared with the brand-name drug.
No cost savings statement is present in the supplied label excerpts.
Information regarding specific patent expiration dates for Clarithromycin ER formulations may be found through specialized patent tracking services.
No patent expiration/patent tracking guidance is present in the supplied label excerpts.
DrugPatentWatch.com provides detailed patent information, including expiry dates, for various pharmaceutical products.
No external database or named source information is present in the supplied label excerpts.
Patent status can influence the availability and pricing of both brand-name and generic versions of the drug.
No patent/status-to-availability/pricing relationship is present in the supplied label excerpts.
Contradictions
Important Omissions
Administration instructions: clarithromycin extended-release tablets should be taken with food and swallowed whole (not chewed, broken, or crushed).
Importance:
Moderate
The label excerpt includes a constraint that efficacy and safety for treating other infections (for which other formulations are approved) have not been established.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only on-label clinical content provided aligns with antibacterial stewardship. However, many non-label claims could mislead regarding dosing/frequency, pharmacology, generic equivalence, and cost, which are not supported by the supplied labeling text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are not supported by the supplied FDA-approved labeling excerpts (pricing, coupon/copay programs, ER vs IR pharmacologic claims, generic availability/bioequivalence, and patent information).
Suggested Improvement
Limit claims to the supplied label excerpts: (1) antibacterial stewardship use-only-for-proven/strongly suspected susceptible bacterial infections and (2) administration instructions (take with food; swallow whole). Remove or clearly qualify all pricing, coupon/copay program, generic/bioequivalence, ER pharmacology, dosing-frequency, adherence, and patent-source claims as they are not present in the provided labeling text.